China sets more funds for HIV research

    Updated: 2011-09-15 07:28

    By Shan Juan (China Daily)

      Comments() Print Mail Large Medium  Small 分享按鈕 0

    BANGKOK - China invested more than $18 million in HIV vaccine research and development in 2010, becoming the third largest contributor globally, after the United States and the European Union, according to a report endorsed by UNAIDS.

    Internationally, HIV vaccine research and development (R&D) funding stood at $859 million last year, $9 million less than 2009, while China increased its spending by nearly $4 million over the same period, said the global report issued jointly by international organizations including AIDS Vaccine Advocacy Coalition (AVAC) and Intentional AIDS Vaccine Initiative.

    "The long-term nature of vaccine research will require sustained investments globally and more developing countries like China are expected to shoulder more responsibilities," Kevin Fisher, the coalition's policy director said at the 2011 AIDS Vaccine Conference, which opened on Tuesday.

    Unfortunately, overall global funding for HIV R&D has flattened out since 2000 and some early supporters, such as Canada and Sweden, have cut back, said the report. In the EU, a major contributor, funding has declined by 23 per cent since 2007.

    In contrast, the Chinese government has pledged to further boost funding for HIV vaccine development by at least 20 percent in five years, according to Shao Yiming, director of the virology and immunology department of the National Center for AIDS/STD Control and Prevention.

    Currently, China has four major HIV vaccine candidates under development on the mainland, all financed by the government.

    "Compared with many developed countries like the US, which has dozens of HIV vaccine candidates under development, China needs more to have a better chance of success," Shao said.

    His team is now waiting for approval from China's drug authorities to enter the second phase of the clinical trial for their HIV vaccine candidate, Tiantan.

    Usually a vaccine has to undergo three phases of human trials before being licensed for use, experts said. The first two phases mainly test its safety and the third mainly its efficacy.

    By May, 24 HIV vaccine candidates had entered the human trial stages across the world, including Tiantan, which is the only one from China to have reached that point.

    Shao urged the Chinese government to regularly increase funding for vaccine development, particularly when some attention has been diverted to new prevention measures with proven efficacy.

    "An effective and affordable vaccine is unanimously recognized as the ultimate weapon against HIV/AIDS worldwide," he said.

    "The funding and human resources for vaccine R&D in China should be diversified and stakeholders like charities and industry should join in the effort."

    Currently, all such studies on the mainland are funded and organized by the government, he said.

    Half of the resources come from non-public sectors like pharmaceutical companies and philanthropic organizations, according to Shao.

    As well, Kevin Fisher called on the Chinese government to be more transparent and to collaborate with international researchers in HIV vaccine development.

    He said the Chinese authorities were usually reluctant to share relevant information, such as the amount of investment, with international stakeholders.

    无码人妻丰满熟妇区五十路百度| 亚洲av无码成人精品国产| 中文字幕无码日韩专区免费| 中文字幕精品无码一区二区三区| 久久久噜噜噜久久中文字幕色伊伊 | 最新中文字幕av无码专区| 国产精品无码无在线观看| 免费无码av片在线观看| 免费无码中文字幕A级毛片 | 免费 无码 国产在线观看观| 无码中文人妻视频2019| 免费看无码特级毛片| www日韩中文字幕在线看| 免费无码午夜福利片69| 久久无码av三级| 久久久久久无码Av成人影院| 无码少妇一区二区性色AV| 免费A级毛片无码无遮挡内射| 久久亚洲精精品中文字幕| 日韩精品人妻一区二区中文八零| 久久激情亚洲精品无码?V| 91无码人妻精品一区二区三区L| 久久久久亚洲AV片无码下载蜜桃| 亚洲AV无码专区国产乱码4SE| 久久久久久精品无码人妻| 69堂人成无码免费视频果冻传媒 | 日韩中文字幕在线观看| 亚洲开心婷婷中文字幕| 欧美中文在线视频| 在线免费中文字幕| 最近中文国语字幕在线播放视频| 7777久久亚洲中文字幕| 久久ZYZ资源站无码中文动漫| 亚洲精品中文字幕无码蜜桃| 欧美人妻aⅴ中文字幕| 最近中文字幕精彩视频| 中文字幕在线观看国产| 中文精品无码中文字幕无码专区| 亚洲桃色AV无码| 无码国产精品一区二区免费模式| 日韩丰满少妇无码内射|